Bookmark
Forward
QuickView for Glimepiride (compound)
PubChem
| Name: | glimepiride |
|---|---|
| PubChem Compound ID: | 11787804 |
| Molecular formula: | C43H55ClN6O8S2 |
| Molecular weight: | 883.517 g/mol |
DrugBank
Identification
| Name: | glimepiride |
|---|---|
| Name (isomeric): | DB00222 |
| Drug Type: | small molecule |
| Synonyms: |
Glimepride; Glimepirida; Glimepiridum; Glimepirid
|
| Brand: | Novo-glimepiride, Amaryl, Amarel, Sandoz glimepiride, Ratio-glimepiride, PMS-glimepiride, Endial |
| Brand name mixture: | Avandaryl(glimepiride + rosiglitazone maleate) |
| Category: | Hypoglycemic Agents, Antiarrhythmic Agents, Sulfonylureas, Anti-Arrhythmia Agents, Immunosuppressive Agents |
| CAS number: | 93479-97-1 |
Pharmacology
| Indication: | For concomitant use with insulin for the treatment of noninsulin-dependent (type 2) diabetes mellitus. |
|---|---|
| Pharmacology: | Glimepiride, like glyburide and glipizide, is a "second-generation" sulfonylurea agents. Glimepiride is used with diet to lower blood glucose by increasing the secretion of insulin from pancreas and increasing the sensitivity of peripheral tissues to insulin. |
| Mechanism of Action: |
The mechanism of action of glimepiride in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral tissues to insulin. Glimepiride likely binds to ATP-sensitive potassium channel receptors on the pancreatic cell surface, reducing potassium c...
show more » |
| Absorption: | Completely (100%) absorbed following oral administration. |
| Protein binding: | Over 99.5% bound to plasma protein. |
| Biotransformation: | Hepatic. Following either an intravenous or oral dose, glimepiride is completely metabolized by oxidative biotransformation to a major metabolite, cyclohexyl hydroxymethyl derivative (M1), via the hepatic cytochrome P450 II C9 subsystem. M1 is further metabolized to the carboxyl derivative (M2) by one or several cytosolic enzymes. M1, but not M2, possessed approximately one third of the pharmacologic activity of its parent in an animal model. However, whether the glucose-lowering effect of M1 is clinically significant is not clear. |
| Half Life: | Approximately 5 hours following single dose. |
| Clearance: | 52.1 +/- 16.0 mL/min [Normal subjects with single oral dose] 48.5 +/- 29.3 mL/min [Patients with Type 2 diabetes, with single oral dose] 52.7 +/- 40.3 mL/min [Patients with Type 2 diabetes, with multiple oral dose] 47.8 mL/min [healthy after intravenous (IV) dosing] |
| Toxicity: | Severe hypoglycemic reactions with coma, seizure, or other neurological impairment. |
| Affected organisms: | Humans and other mammals |
Interactions
| Food interaction: |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug interaction: |
|
Targets
Enzymes
